TODAY'S HEADLINES

Advanced ovarian cancer drug approved

FDA recently approved rucaparib (Rubraca) tablets to treat patients with deleterious BRCA mutation (germline and/or somatic)-associated advanced ovarian cancer, who have been treated with 2 or more chemotherapies. Read more

FDA green lights first treatment for rare spinal disease

FDA approved nusinersen (Spinraza), the first drug to treat children and adults with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement. Read more

CONTINUING PHARMACY EDUCATION

Key cogs in the management of Parkinson's disease

This month's CE activity, "Key cogs in the management of Parkinson's disease," is open for pharmacists and pharmacy technicians.
The goal of this activity is to assist pharmacists and pharmacy technicians in managing difficult-to-treat symptoms of Parkinson's disease.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

New drug indication could net more than $1 billion

FDA's approval of a new indication for one major diabetes drug could net a pharma company more than $1 billion in sales. Read more

December 28, 2016

Related Articles

FDA approves expansion of Avastin in ovarian cancer

Drug approved for rare lung disease that strikes younger women